Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis

Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D lev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Armita Abolghasemi, Claudia Manca, Fabio A. Iannotti, Melissa Shen, Nadine Leblanc, Sébastien Lacroix, Cyril Martin, Nicolas Flamand, Vincenzo Di Marzo, Cristoforo Silvestri
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	endocannabinoidome endocannabinoids gut microbiome vitamin D olanzapine antipsychotic Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/300e562b0b634263805e70cb63ddfb72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:300e562b0b634263805e70cb63ddfb72
record_format	dspace
spelling	oai:doaj.org-article:300e562b0b634263805e70cb63ddfb722021-11-25T17:55:42ZAssessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis10.3390/ijms2222123611422-00671661-6596https://doaj.org/article/300e562b0b634263805e70cb63ddfb722021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12361https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D levels. The gut microbiota and endocannabinoidome (eCBome) are significant regulators of both metabolism and mental health, but their role in the development of atypical antipsychotic drug metabolic side-effects and their interaction with vitamin D status is unknown. We studied the effects of different combinations of vitamin D levels and atypical antipsychotic drug (olanzapine) exposure on whole-body metabolism and the eCBome-gut microbiota axis in female C57BL/6J mice under a high fat/high sucrose (HFHS) diet in an attempt to identify a link between the latter and the different metabolic outputs induced by the treatments. Olanzapine exerted a protective effect against diet-induced obesity and insulin resistance, largely independent of dietary vitamin D status. These changes were concomitant with olanzapine-mediated decreases in <i>Trpv1</i> expression and increases in the levels of its agonists, including various <i>N</i>-acylethanolamines and 2-monoacylglycerols, which are consistent with the observed improvement in adiposity and metabolic status. Furthermore, while global gut bacteria community architecture was not altered by olanzapine, we identified changes in the relative abundances of various commensal bacterial families. Taken together, changes of eCBome and gut microbiota families under our experimental conditions might contribute to olanzapine and vitamin D-mediated inhibition of weight gain in mice on a HFHS diet.Armita AbolghasemiClaudia MancaFabio A. IannottiMelissa ShenNadine LeblancSébastien LacroixCyril MartinNicolas FlamandVincenzo Di MarzoCristoforo SilvestriMDPI AGarticleendocannabinoidomeendocannabinoidsgut microbiomevitamin DolanzapineantipsychoticBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12361, p 12361 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	endocannabinoidome endocannabinoids gut microbiome vitamin D olanzapine antipsychotic Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	endocannabinoidome endocannabinoids gut microbiome vitamin D olanzapine antipsychotic Biology (General) QH301-705.5 Chemistry QD1-999 Armita Abolghasemi Claudia Manca Fabio A. Iannotti Melissa Shen Nadine Leblanc Sébastien Lacroix Cyril Martin Nicolas Flamand Vincenzo Di Marzo Cristoforo Silvestri Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
description	Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D levels. The gut microbiota and endocannabinoidome (eCBome) are significant regulators of both metabolism and mental health, but their role in the development of atypical antipsychotic drug metabolic side-effects and their interaction with vitamin D status is unknown. We studied the effects of different combinations of vitamin D levels and atypical antipsychotic drug (olanzapine) exposure on whole-body metabolism and the eCBome-gut microbiota axis in female C57BL/6J mice under a high fat/high sucrose (HFHS) diet in an attempt to identify a link between the latter and the different metabolic outputs induced by the treatments. Olanzapine exerted a protective effect against diet-induced obesity and insulin resistance, largely independent of dietary vitamin D status. These changes were concomitant with olanzapine-mediated decreases in <i>Trpv1</i> expression and increases in the levels of its agonists, including various <i>N</i>-acylethanolamines and 2-monoacylglycerols, which are consistent with the observed improvement in adiposity and metabolic status. Furthermore, while global gut bacteria community architecture was not altered by olanzapine, we identified changes in the relative abundances of various commensal bacterial families. Taken together, changes of eCBome and gut microbiota families under our experimental conditions might contribute to olanzapine and vitamin D-mediated inhibition of weight gain in mice on a HFHS diet.
format	article
author	Armita Abolghasemi Claudia Manca Fabio A. Iannotti Melissa Shen Nadine Leblanc Sébastien Lacroix Cyril Martin Nicolas Flamand Vincenzo Di Marzo Cristoforo Silvestri
author_facet	Armita Abolghasemi Claudia Manca Fabio A. Iannotti Melissa Shen Nadine Leblanc Sébastien Lacroix Cyril Martin Nicolas Flamand Vincenzo Di Marzo Cristoforo Silvestri
author_sort	Armita Abolghasemi
title	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_short	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_full	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_fullStr	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_full_unstemmed	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_sort	assessment of the effects of dietary vitamin d levels on olanzapine-induced metabolic side effects: focus on the endocannabinoidome-gut microbiome axis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/300e562b0b634263805e70cb63ddfb72
work_keys_str_mv	AT armitaabolghasemi assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT claudiamanca assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT fabioaiannotti assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT melissashen assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT nadineleblanc assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT sebastienlacroix assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT cyrilmartin assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT nicolasflamand assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT vincenzodimarzo assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis AT cristoforosilvestri assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
_version_	1718411792578772992

Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis

Ejemplares similares